Abstract Number: 131 • 2017 Pediatric Rheumatology Symposium
Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes
Background/Purpose: Monocytes are bridging natural and acquired immunity. Information about JAK signaling in monocytes is scarce especially in an inflammatory milieu. JAK-inhibition is a promising…Abstract Number: 71 • 2017 Pediatric Rheumatology Symposium
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is currently classified by the International League of Associations for Rheumatology (ILAR) classification criteria. It is characterized by severe…Abstract Number: 98 • 2017 Pediatric Rheumatology Symposium
Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus
Background/Purpose: According to the Center for Disease Control, 46.8% of high school students surveyed in 2013 have been sexually active. Of those surveyed 34% had…Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…Abstract Number: 88 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium
Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin
Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…Abstract Number: 46 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…Abstract Number: 134 • 2017 Pediatric Rheumatology Symposium
Akkermansia Muciniphila May Be Permissive to Arthritis in the K/BxN Mouse Model of Arthritis
Background/Purpose: Studies have identified abnormalities in the microbiota of patients with arthritis. To evaluate the pathogenicity of human microbiota, we performed fecal microbial transplantation (FMT)…Abstract Number: 41 • 2017 Pediatric Rheumatology Symposium
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients (pts) with polyarticular-course juvenile idiopathic…Abstract Number: 136 • 2017 Pediatric Rheumatology Symposium
14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…Abstract Number: 37 • 2017 Pediatric Rheumatology Symposium
Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study
Background/Purpose: Shared Decision Making (SDM) is an interactive process whereby the clinician-patient-parent triad arrives at a treatment decision after reviewing treatment goals, best available medical…Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…Abstract Number: 4 • 2017 Pediatric Rheumatology Symposium
Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome
Background/Purpose: Targeting host-microbiota interactions to limit production of pathogenic myeloid cells that fuel chronic inflammatory responses is of therapeutic interest. Recent evidence suggests that this may…Abstract Number: 73 • 2017 Pediatric Rheumatology Symposium
Factors Associated with Etoposide Usage in Children with Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Although macrophage activation syndrome (MAS) has been reported in association with almost all rheumatic diseases, it is by far most common in systemic juvenile…Abstract Number: 10 • 2017 Pediatric Rheumatology Symposium
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…
ACR Meeting Abstracts